Full Study Name
NIGHT – Natural History of the Progression of Choroideremia Study
Local Principal Investigator
Prof Graeme Black
The objective of the study is to gain a better understanding of the progression of choroideremia (CHM) and add to the knowledge base for this rare disease.
- Are willing and able to provide informed consent for participation in the study.
- Are male and ≥18 years of age.
- Have a clinical phenotype and confirmed genetic diagnosis of CHM.
- Have active disease clinically visible within the macular region.
- Are willing and able to undergo ophthalmic examinations once every 4 months for up to 20 months.
- Have a BCVA better than or equal to 6/60 (20/200; decimal 0.1; LogMAR 1.0; 34-38 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) in at least one eye
- Have a history of amblyopia in the eligible eye.
- Have any other significant ocular or non-ocular disease/disorder in the eligible eye which, in the opinion of the investigator, may put the subject at risk because of participation in the study, influence the results of the study or influence the subject’s ability to participate in the study.
- Have participated in an interventional research study in the past 6 months.
MFT, Oxford University Hospital, Moorfields Hospital (London), EU and worldwide sites
For more information click here